Group 1 - The core point of the article is the election of Jin Xi, a 26-year-old, as the chairman and general manager of Hongming Co., Ltd., making him one of the few "post-2000" chairmen in A-shares [2][6] - Jin Xi is the son of Jin Jian and Cai Tiehui, who are the controlling shareholders of Hongming Co., Ltd., holding over 60% of the company's shares [6] - Hongming Co., Ltd. specializes in providing high-quality packaging boxes, paper-plastic intelligent equipment, and complete automation solutions, with its products widely used in various packaging sectors [7] Group 2 - The company reported a net profit of -16.77 million yuan in 2023 and continued to incur losses in 2024, with a net profit of -9.77 million yuan [7][8] - Despite a 34.49% growth in overseas market business, the company faced slow recovery in downstream market demand and intense industry competition, leading to a decline in product sales prices [8] - For 2025, the company anticipates a net loss of between 12 million to 18 million yuan, attributed to low downstream investment demand and increased competition [8]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01105 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 2,354,256,546 | HKD | | 0.2 | HKD | | 470,851,309.2 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 2,354,256,546 | HKD | | 0.2 | HKD | | 470,851,309.2 | | 2. 股份分類 | 優先股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 否 | | | --- | -- ...

每经记者｜陈鹏丽 每经编辑｜陈柯名 陈俊杰 官网截图 经董事会提名，新一届董事会董事候选人里包括金玺、王佩仪、刘江、钟水东、左英魁、朱智伟。《每日经济新闻》记者注意到，金玺出生于2000年，年 约25岁，为鸿铭股份创始人、董事长金健的儿子。此外，王佩仪生于1999年，也才26岁。 根据董事候选人名单，金健及其妻子、公司董事蔡铁辉将双双退出新一届董事会。这意味着，鸿铭股份将要迎来"二代"接班。公开资料显示，金玺本科毕 业于纽约大学，研究生毕业于哥伦比亚大学。去年12月至今担任董事长助理。 鸿铭股份于2022年底登陆创业板，之后业绩一直表现不佳。2023年和2024年，公司连续两年归母净利润为负值。此次拥有海外名校背景的"创二代"走向台 前，能否带领公司走出业绩困境？ 1月21日晚间，广东东莞一家上市公司鸿铭股份（SZ301105）发布公告称，公司第三届董事会任期即将届满，正启动新一届董事会的换届选举工作。 另一名候选人王佩仪生于1999年。她2022年7月至今就职于鸿铭股份，担任市场营销中心国外销售部经理。记者注意到，关于王佩仪具体身份，公开资料 并不多。鸿铭股份称，王佩仪与公司其他董事、高级管理人员及持有5% ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 星島新聞集團有限公司 呈交日期: 2026年1月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01105 | 說明 | | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | | 法定/註冊股本 | | | 上月底結存 | | | 2,354,256,546 | HKD | | | 0.2 HKD | | | 470,851,309.2 | | 增加 / 減少 (-) | | | | | | | HKD | | | | | 本月底結存 | | | 2,354,256,546 | HKD | | | 0.2 HKD | | | 470 ...

Core Viewpoint - The collaboration between 加科思 and AstraZeneca involves a total transaction value of $20.15 billion, with 加科思's drug JAB-23E73 being the focal point, yet the stock price of 加科思 fell significantly on the first trading day after the announcement [1][2]. Group 1: Transaction Details - 加科思 will receive an upfront payment of $100 million, with potential milestone payments of up to $1.915 billion based on development and commercialization progress, along with royalties on net sales outside of China [1]. - JAB-23E73 targets various KRAS mutations, which are present in approximately 23% of all cancer patients, and is currently undergoing Phase I clinical trials in China and the U.S. [1]. Group 2: Partnership with AstraZeneca - AstraZeneca will have exclusive rights to develop and commercialize the drug outside of China, while 加科思 will co-develop and commercialize it within China [2]. - 加科思 chose AstraZeneca due to its significant revenue from oncology, which is projected to account for 41% of its income in 2024, and its established global clinical network [2]. Group 3: Market Reaction and Stock Performance - Following the announcement, 加科思's stock dropped by 17% at one point, closing down 13.58% at HKD 7.83, with a total market capitalization of HKD 6.16 billion [2]. - Analysts noted that the $100 million upfront payment may not meet market expectations, which were around $200 million [2]. Group 4: Management's Perspective - The CEO of 加科思 stated that the upfront payment represents 5% of the total transaction value, which is considered reasonable compared to industry standards [3]. - The CEO also addressed the stock price decline, attributing it to the early-stage development of the biotech sector in Hong Kong and the shift in investor focus from long-term value to short-term gains [3].

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 星島新聞集團有限公司 呈交日期: 2025年12月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01105 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 2,354,256,546 | HKD | | 0.2 | HKD | | 470,851,309.2 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 2,354,256,546 | HKD | | 0.2 | HKD | | 470,851,309.2 | | 2. ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 星島新聞集團有限公司 呈交日期: 2025年11月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01105 | 說明 | | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | | 法定/註冊股本 | | | 上月底結存 | | | 2,354,256,546 | HKD | | | 0.2 HKD | | | 470,851,309.2 | | 增加 / 減少 (-) | | | | | | | HKD | | | | | 本月底結存 | | | 2,354,256,546 | HKD | | | 0.2 HKD | | | 47 ...

Core Viewpoint - A new individual business, Yuxi Hongta District Xingdao Dessert Shop, has been established with a registered capital of 150,000 RMB, focusing on food service and sales [1] Company Summary - The legal representative of the newly established dessert shop is He Jun Dong [1] - The business scope includes licensed projects such as catering services and food sales, which require approval from relevant authorities before operation [1] - The general projects include online sales of pre-packaged food and retail of fresh fruits, which can be conducted independently with a business license [1]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 星島新聞集團有限公司 呈交日期: 2025年10月2日 I. 法定/註冊股本變動 | 2. 股份分類 | 優先股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 0 | 說明 | | 5%累積可贖回可轉換優先股 | | | | | | | | 法定/註冊股份數目 | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 1,291,486,908 | HKD | | 0.1 HKD | | 129,148,690.8 | | 增加 / 減少 (-) | | | | | | HKD | | | | 本月底結存 | | | 1,291,486,908 | HKD | | 0.1 HKD | | 129,148,690.8 | 本月底法定/註冊股本總額： ...

Core Viewpoint - Hong Kong Sing Tao News Corporation Limited announced the resignation of its Executive Director and Co-CEO, Cai Jin, effective immediately, due to personal commitments [1] Group 1: Resignation Details - Cai Jin has formally submitted his resignation to the board, which is effective immediately [1] - Following his resignation, Cai Jin will also cease to serve as the authorized representative under the Hong Kong Stock Exchange Listing Rules and the Companies Ordinance [1] - Cai Jin clarified that there are no disagreements with the board and no other matters related to his resignation that need to be brought to the attention of shareholders or the Hong Kong Stock Exchange [1] Group 2: Background Information - Cai Jin joined Sing Tao News Group in June 2021 as Chief Operating Officer and was appointed Executive Director and Co-CEO in October 2021 [1] - During his tenure, he promoted business enhancement and new media reforms, launching several electronic platforms such as "Sing Tao Headlines" and achieving breakthroughs in cross-industry collaborations [1] - He also organized multiple socially impactful events [1]